D9 Pharmaceuticals
The next generation of medical cannabis
Our vision
Innovators. Dreamers. Doers.
At D9 Pharmaceuticals we are a team of ambitious and dynamic entrepreneurs dedicated in creating the next generation of medical cannabis cultivation. Our aim is to create a medical cannabis production unit which combines economic viability and environmental sustainability. Unlike similar projects on medical cannabis, this project involves the implementation of a unique technology that reduces CO2 emissions.
Our distinctive competitive advantage against other suppliers, is based on the ultra-high quality of the final product which emerges from the state of-the-art cultivation technology and the unique techniques we use for the optimisation of yields and quality. Our supercritical carbon dioxide product extraction method in combination with our unique environmental technology for the processing and reduction of Co2, creates an innovative, efficient, and unique project at a global scale.
The Project
Unique. Efficient. Profitable.
The project is expected to generate approximately €26m in revenues in year 1 that will grow to €49m by year. 5. The operating profit margin is 57% in year 1 yielding EBIDTA of €15m. Due to economies of scale, the operating profit margin will grow to 66.5% in year 5 generating EBIDTA of €32.7m.
Key Characteristics
-
1844m2 flowering room after GACP protocols implementation (hybrid Greenhouse)
-
1000m2 of pharmaceutical processing facilities, including more than 500m2 EU- GMP classified area
-
Both APIs (Active Pharmaceutical Ingredients) and finished products capabilities
-
Both high-THC and high-CBD strain cultivation, minor cannabinoids included
-
4 crops per year yielding 4,86 tons per year in year 1 and 2, and 6,08 tons in year 3 onwards, of dried flower per year.
The Opportunity
Growth. Sustainability. Returns.
The total cost of the investment is estimated at €18m. This includes the set-up costs and the working capital required during the negative cash flows period (year 0 to year 1).
An initial equity contribution of €10. 8m (60% of the investment cost) will allow the project to be considered for the Greek government financial subsidy scheme for the remaining 40% of the total investment cost. The project has been developed in order to be fully compliant with the conditions required by the Greek legislation to receive direct financial subsidies (e.g., cash) up to 40% of the project budget cost.
The project team is seeking a strategic investor(s) to contribute up to 60% of the total investment cost (€10.8m) in exchange for up to 80% of the equity.
Contact Us
We are currently delivering investor information sessions in the context of our active round of raising funding.
If you are interested to know more about our project, please contact us using the form below.